Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands
Open Access
- 1 September 2017
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 403, 98-107
Abstract
No abstract availableKeywords
Funding Information
- Yorkshire Cancer Research (BPP 046)
- NIHR Research & Innovation Division (R116577)
- Strategic Project Funding 2013
- Manchester Pharmacy School Fellowship
This publication has 45 references indexed in Scilit:
- EO9 (Apaziquone): from the clinic to the laboratory and back againBritish Journal of Pharmacology, 2012
- Anticancer Activity of Silver–N‐Heterocyclic Carbene Complexes: Caspase‐Independent Induction of Apoptosis via Mitochondrial Apoptosis‐Inducing Factor (AIF)ChemMedChem, 2012
- Switching from aerobic glycolysis to oxidative phosphorylation modulates the sensitivity of mantle cell lymphoma cells to TRAILOncogene, 2012
- Enhanced cytotoxicity of silver complexes bearing bidentate N-heterocyclic carbene ligandsDalton Transactions, 2012
- Small molecule inhibitors of mammalian thioredoxin reductaseFree Radical Biology and Medicine, 2012
- Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and IIJBIC Journal of Biological Inorganic Chemistry, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Analysis of Food and Drug Administration–Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell LinesMolecular Cancer Therapeutics, 2010
- The Structure of Human Thioredoxin Reductase 1 Provides Insights into C-terminal Rearrangements During CatalysisJournal of Molecular Biology, 2007